Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera by Han, Min et al.
Diagnosis of Parkinson’s Disease Based on Disease-
Specific Autoantibody Profiles in Human Sera
Min Han
1,2., Eric Nagele
3., Cassandra DeMarshall
1,2, Nimish Acharya
1,2, Robert Nagele
2,3*
1University of Medicine and Dentistry of New Jersey-Graduate School of Biomedical Sciences at the School of Osteopathic Medicine, Stratford, New Jersey, United States
of America, 2New Jersey Institute for Successful Aging, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America, 3Durin
Technologies, Inc. New Brunswick, New Jersey, United States of America
Abstract
Parkinson’s disease (PD), hallmarked by a variety of motor disorders and neurological decline, is the second most common
neurodegenerative disease worldwide. Currently, no diagnostic test exists to identify sufferers, and physicians must rely on a
combination of subjective physical and neurological assessments to make a diagnosis. The discovery of definitive blood-
borne biomarkers would be a major step towards early and reliable diagnosis. Despite attention devoted to this search, such
biomarkers have remained elusive. In the present study, we used human protein microarrays to reveal serum autoantibodies
that are differentially expressed among PD and control subjects. The diagnostic significance of each of these autoantibodies
was evaluated, resulting in the selection of 10 autoantibody biomarkers that can effectively differentiate PD sera from
control sera with a sensitivity of 93.1% and specificity of 100%. PD sera were also distinguishable from sera obtained from
Alzheimer’s disease, breast cancer, and multiple sclerosis patients with accuracies of 86.0%, 96.6%, and 100%, respectively.
Results demonstrate that serum autoantibodies can be used as highly specific and accurate biomarkers for PD diagnosis
throughout the course of the disease.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive motor
system disorder inflicting profound social and economic costs
worldwide. It is the second most common neurodegenerative
disorder after Alzheimer’s disease (AD), affecting more than 1% of
55-year-old individuals and more than 3% of those over the age of
75 [1]. The primary symptoms of PD include tremor, rigidity,
bradykinesia, and postural instability [2]. The cardinal patholog-
ical feature of PD is the loss of dopaminergic neurons in the
substantia nigra, a brain region involved in coordination and
control of muscle activity [3,4]. Although PD manifests primarily
as a motor disability, recent studies reveal many pre-motor
symptoms that suggest an onset of PD pathology years before
characteristic symptoms appear [5–7]. By the time a diagnosis is
made, at least one-third of substantia nigra neurons and striatal
dopaminergic fibers are already lost [8,9].
Despiteyearsofresearch,thereisnoonetestortechniquethatcan
provide a conclusive primary diagnosis of PD. Current diagnostic
methods are based on medical history evaluation and a combination
of physical and neurological assessments [10,11]. Standard practices
for theseassessments, suchasthe Unified Parkinson’s Disease Rating
Scale (UPDRS) [12,13], have aided tremendously in clinical staging
of the disease, but fail to detect PD before the onset of initial motor
symptoms. Additional techniques, such as CT, MRI, and PET
neuroimaging, may be used to rule out other neurological disorders,
but rarelydotheydetect any abnormality thatcan be directly related
to the onset of PD [14]. There are also no laboratory tests utilizing
blood, cerebrospinal fluid, or urine samples that have proven to be
effective in primary diagnosis or confirmation of PD. Thus, there is
still pressing need for an accurate, relatively non-invasive, and
affordable PD diagnostic test. This is particularly true given
widespread recognition that early detection facilitating early
treatment helps to slow the progression of the disease, minimize
symptoms, and improve the overall quality of life [15].
We have recently demonstrated the ubiquitous presence of
autoantibodies in human sera, regardless of patient age or health
status [16,17]. These findings led us to test the hypothesis that the
presence of ongoing disease causes consistent, disease-specific
perturbations of autoantibody profiles in the blood. In the case of
AD, we have previously used human protein microarrays to
compare disease and control serum autoantibody profiles and
detected disease-specific autoantibody biomarkers capable of
differentiating blinded AD and control serum samples with a
sensitivity of 96.0% and specificity of 92.5% [18]. In the present
study, we again used human protein microarrays to detect and
measure disease group- and control group-specific variations in
autoantibody expression patterns in an effort to identify potential
diagnostic biomarkers of PD. Our results confirm that autoantibody
expression profiles can be used to select a relatively small subset of
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32383autoantibody biomarkers that can detect the presence of PD with
great accuracy and specificity using only a small sample of blood.
Materials and Methods
Ethics Statement
Approval for the use of blood samples for this study was
obtained from the UMDNJ-Stratford Institutional Review Board.
Human Serum Samples
Twenty-nine Parkinson’s disease (PD) serum samples, 50 AD
samples, and 40 control samples were obtained from Analytical
Biological Systems, Inc. (Wilmington, DE). Thirty breast cancer (BC)
serum samples and 10 multiple sclerosis (MS) serum samples were
obtained from Asterand, Inc. (Detroit, MI). In an attempt to develop a
diagnostic with broad application to all PD patients at all stages of the
disease, our PDserum pool contained samples from early, progressive
and late stage PD subjects. All samples were handled by standard
procedures and stored at 280uC. Diagnosis of PD was based on a
clinical evaluation based on Gelb criteria [11]. Demographic
characteristics of the study population are shown in Table 1.
Human Protein Microarrays
To identify autoantibodies in human sera, we used Invitrogen’s
ProtoArray v5.0 Human Protein Microarrays (Cat. No. -
PAH0525020, Invitrogen, Carlsbad, CA, USA), each containing
9,486 unique human protein antigens (www.invitrogen.com/proto-
array). All proteins were expressed as GST fusion proteins in insect
cells, purified under native conditions, and spotted in duplicate onto
nitrocellulose-coatedglassslides.Allarrayswereprobedandscanned
according to the manufacturer’s instructions using commercially
prepared reagents. Briefly, microarray slides were blocked (Blocking
Buffer, Cat. No. PA055, Invitrogen) and then incubated with serum
samples, diluted 1:500 in washing buffer. After washing, the arrays
were probed with anti-human IgG (H+L) conjugated to AlexaFluor
647 (Cat. No. A-21445, Invitrogen). Arrays were then washed, dried,
and immediately scanned with a GenePix 4000B Fluorescence
Scanner (Molecular Devices, Sunnyvale, CA, USA).
Microarray Data Analysis
The fluorescence data from each microarray was acquired by
Genepix Pro analysis software after scanning, and then synced with
Invitrogen’s lot-specific Genepix Array List (GAL) files. The resulting
Genepix Results (GPR) files were then imported into Invitrogen’s
Prospector 5.2 for analysis. All data is MIAME compliant and the
raw data has been deposited in a MIAME compliant database
(GEO) under the accession number GSE29654. The ‘‘group
characterization’’ and ‘‘two - group comparison’’ features in the
IRBP Toolbox allowed for M-statistical analysis of autoantibody
expression. Sorting detectable autoantibodies by difference of
prevalence between PD and control groups in descending order,
we selected the top 10 as our potential diagnostic biomarkers.
The selected biomarkers were re-verified as significant by
Predictive Analysis for Microarrays (PAM) – an independent algorithm
relying on nearest shrunken centroid analysis to identify proteins
acting as significant class-differentiators. The predictive classifica-
tion accuracy of the identified biomarkers was tested with Random
Forest (RF) using the default settings, another significance algorithm
run as an R package (v 2.12.1). In RF, partitioning trees are built
by successively splitting the samples according to a measure of
statistical impurity at a given node until terminal nodes are as
homogenous as possible. Classification accuracy for a given set of
diagnostic biomarkers is reported in a confusion matrix and
misclassification as an Out-Of-Bag (OOB) error score.
Results
Selection of Autoantibody Biomarkers for PD Diagnosis
A total of 69 human serum samples (29 PD and 40 controls;
Table 1) were assigned to either a Training Set (15 PD, 20 control) or
Testing Set (14 PD, 20 control), each containing equal proportions of
early-, progressive-, and late-stage PD samples as well as older and
younger controls. To identify potential diagnostic autoantibodies for
PD, we probed human protein microarrays, each containing 9,486
native antigens, with Training Set sera and analyzed the data as
described in Materials and Methods (Fig. 1). Prospector analysis
software determined that 780 autoantibodies had a significantly
higher prevalence in the PD group than in the control group (p,0.01)
and thus represent potential PD biomarkers. We selected the 10
autoantibody biomarkers that demonstrated the largest difference in
group prevalence between PD and controls to serve as our diagnostic
indicators (Table 2). The differential expression of these 10
autoantibody biomarkers is shown in Figure 2. As an independent
verification of the 10 biomarkers selected, we re-evaluated our data
with Predictive Analysis for Microarrays (PAM)[ 1 9 ] .PAM confirmed that
the 10 biomarkers originally selected by Prospector were among the
most significant classifiers of PD and controls.
Verification of Biomarkers via Training and Testing Set
Analysis
To assess the Training and Testing set classification accuracies
of the 10 selected PD biomarkers, we used Random Forest (RF) [20].
RF is a statistical algorithm that creates voting classes of decision-
making trees to evaluate the significance of each marker and
classify samples. Using our 10 biomarkers to ‘‘diagnose’’ the
Training Set (n=35; 15 PD and 20 control), RF had an overall
accuracy of 97.1% [Out-of-Bag (OOB) Error 2.9%, a positive
predictive value (PPV) of 100%, and a negative predictive value
(NPV) of 95.2%]. When the same 10 biomarkers were used to
classify Testing Set sera (n=34; 14 PD and 20 control), which
played no part in the biomarker selection process, RF distinguished
PD samples from controls with equal accuracy (prediction error of
2.9%, PPV of 100.0%, and NPV of 95.2%). When the 10
autoantibody biomarkers were used to classify all PD and control
samples simultaneously (n=69; 29 PD, 40 control) in RF, they did
so with a 93.1% sensitivity and 100% specificity.
Differentiation of PD from Other Diseases
Using the 10 selected autoantibody biomarkers, PD samples
were correctly differentiated from controls with a high and
consistent accuracy (Table 3). But to test the biomarkers for disease
Table 1. Demographics of Serum Donors.
Group n Age Sex
Mean Range (% male)
Parkinson’s Disease 29 74.0 53–88 55%
Alzheimer’s Disease 50 78.5 61–97 40%
Multiple Sclerosis 10 46.0 27–59 30%
Breast Cancer 30 46.7 32–54 0%
Controls 40 40.4 19–86 82%
–Older Control 20 57.7 51–86 100%
–Younger Control 20 24.7 19–30 65%
doi:10.1371/journal.pone.0032383.t001
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neurological and neurological diseases. To accomplish this, we
used our 10 selected biomarkers to differentiate 30 breast cancer
serum samples from the 29 PD samples. RF reported an OOB
Error of 3.39% (PPV and NPV of 93.5% and 100%, respectively).
These results are similar to those of the PD versus control trials
described above and demonstrate that there is no diagnostic bias
toward disease in general. To verify biomarker specificity against
another central nervous system disorder, we used Multiple
Sclerosis (MS) sera as a neurologically diseased control. Results
show that our 10 PD autoantibody biomarkers can distinguish PD
and MS samples with 100% accuracy (Table 3).
These results, combined with the previous work in which we
demonstrated that PD can be distinguished from AD using only
five autoantibody biomarkers [18], provide further confirmation
that these biomarkers can be used to generate a specific and
reliable PD diagnostic.
Discussion
Parkinson’s disease (PD) is a progressive motor system disorder
that affects over five million people worldwide. No diagnostic test
is yet available. In addition to causing patient anguish, this lack of
confirmation hinders our ability to test potential disease-modifying
drugs and other neuroprotective strategies. Identification of early-
stage PD is the most difficult to achieve; pre-clinical detection is
currently impossible. Identification of blood-borne biomarkers for
accurate diagnosis and early detection of PD has long been a
major goal since this is required for early patient access to therapy.
In the present study, we have confirmed that autoantibody
expression profiles can be used to select a relatively small subset of
autoantibody biomarkers that can detect the presence of PD with
great sensitivity and specificity using only a small sample of blood.
A PD Diagnostic Based on Disease-Associated
Autoantibody Profiles
Using human protein microarrays, we have previously demon-
strated that the number of autoantibodies detectable in human
sera is surprisingly high, averaging over one thousand as detected
by this method but displaying wide individual variation [18].
Although the function of such a large number of autoantibodies is
unknown, we have found that the presence of disease causes
specific perturbations in autoantibody profiles that are useful for
Figure 1. Biomarker selection and training/testing analysis. Before biomarker selection, our total sample pool was split into two randomized
groups: the Training Set and Testing Set. Prospector and PAM statistical analyses were performed on the Training Set to identify the top 10 most
significant autoantibody classifiers of PD and control. We then verified the diagnostic accuracy of these selected biomarkers by using Random Forest
to predict sample classification in the Training Set, Testing Set, and then both sets combined.
doi:10.1371/journal.pone.0032383.g001
Table 2. Identity and Significance of 10 PD vs. Control Diagnostic Biomarkers.
Database ID Description Prevalence in PD Prevalence in Controls p
NM_001544.2 Intercellular adhesion molecule 4 (Landsteiner-Wiener blood
group) (ICAM4), transcript variant 1
93.55% 2.38% 1.73E-18
NM_024754.2 Pentatricopeptide repeat domain 2 (PTCD2) 90.32% 7.14% 9.40E-13
BC051695.1 FERM domain containing 8 (FRMD8) 87.10% 4.76% 1.31E-14
PHR5001 Recombinant human CTLA-4/Fc 87.10% 14.29% 6.14E-11
NM_006790.1 Myotilin (MYOT) 90.32% 21.43% 5.66E-10
NM_032855.1 Hematopoietic SH2 domain containing (HSH2D) 87.10% 7.14% 1.71E-13
BC005858.1 Fibronectin 1 (FN1) 90.32% 14.29% 7.39E-08
NM_003141.2 Tripartite motif-containing 21 (TRIM21) 80.65% 9.52% 1.07E-10
BC094687.1 Elongation factor 1-alpha 1 87.10% 7.14% 3.03E-10
BC027617.1 Poly(A) binding protein, cytoplasmic 3 (PABPC3) 74.19% 11.91% 0.000805
doi:10.1371/journal.pone.0032383.t002
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of autoantibodies that allowed us to identify and test diagnostic
biomarkers for Alzheimer’s disease (AD) [18]. The present study
demonstrates that PD is also linked to characteristic alterations in
serum autoantibody expression profiles. Just as in AD, these
changes allow for the unbiased identification and selection of
specific autoantibodies that can effectively function as diagnostic
biomarkers. We have shown here that with only 10 autoantibody
biomarkers, PD serum samples were readily distinguished from
control sera with a sensitivity of 93.1% and a specificity of 100%.
The most rigorous test of the significance and predictive value of
diagnostic biomarkers is validation in a variety of circumstances.
The 10 PD autoantibody biomarkers were selected using a
Training Set of samples and verified using an independent Testing
Set of samples that played no role in their selection and still
provided a sensitivity of 92.8% and specificity of 100%.
Figure 2. Differential expression of identified PD-specific autoantibody biomarkers in PD and control sera. Microarray fluorescence
values reflecting individual serum autoantibody titers demonstrate the differences in the serum expression of the selected ten PD-specific
autoantibody biomarkers in PD (n=29) and control (n=40) sera (A–I).
doi:10.1371/journal.pone.0032383.g002
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differentiating PD sera from other diseased sera, including MS
and breast cancer. Additionally, PD and Alzheimer’s disease (AD)
are known to be even more closely related and are often co-morbid
with many similarities that can sometimes make it difficult to
clearly distinguish these two diseases by conventional means alone
[21,22]. We previously demonstrated that with as few as only five
autoantibody biomarkers, it was possible to differentiate PD
samples from AD samples [18]. Diagnosing PD from AD, breast
cancer, and multiple sclerosis, we achieved accuracies of 86.0%,
96.6% and 100%, respectively, demonstrating no diagnostic bias
toward disease.
Multiplicity of Differential Autoantibodies
As in our study of AD biomarkers [18], we detected a large
number of differentially expressed autoantibodies in the PD and
control groups. Prospector identified 96 differentiating autoantibod-
ies with a p-value of less than 0.0001 and group prevalence
differences of over 40%, all of which are potentially useful for PD
diagnostics. Importantly, this evaluation of significance was
duplicated by the other statistical algorithms used here, PAM
and RF. Most autoantibodies considered as significant diagnostic
biomarkers by one program were repeatedly selected as significant
by the other two. As shown for AD, this finding suggests that many
combinations of autoantibody biomarkers can be successfully used
to distinguish PD sera from control sera with varying accuracies.
Given the large number of differentially expressed autoantibodies
present in sera from patients with PD and AD, two high-
prevalence neurodegenerative diseases with some common
pathology, we find it likely that they share a similar mechanism
for autoantibody generation.
Possible Origin of Diagnostic Autoantibodies
The underlying reason for the presence and abundance of
autoantibodies in human sera, especially in younger and healthy
individuals, is unknown. Although some autoantibodies may be
remnants of past disease and reflect a history of immunological
activity, many may also be present as a result of ongoing or current
disease. We suggest that the presence of an active disease, resulting
in chronic cell damage and death, causes the production and
release of cellular debris, some of which is antigenic. For example,
in PD, the early and somewhat selective loss of dopaminergic
neurons in the substantia nigra would provide a chronic, yet cell-
type-specific source of such proteins and their breakdown
products. These materials released to the surrounding interstitial
fluid would eventually re-enter the blood and lymph, encounter
the immune surveillance system and presumably elicit an
autoimmune response. We propose that this immune response
leads to the production and appearance of a relatively large
number of autoantibodies in the blood which could conceivably be
involved in clearance of debris generated by the presence of
disease. Since different cell types share many common proteins,
only a very small subset of protein targets and their corresponding
autoantibodies would be expected to be truly cell-type specific, and
thus useful for disease detection and diagnostics. A similar scenario
has recently been proposed to account for the presence of
autoantibodies that useful for the diagnosis of Alzheimer’s disease
in the blood of patients suffering from this devastating disease [18].
In PD, AD, and a number of other neurodegenerative diseases,
earlier stages of disease are known to be more focal and associated
with a more selective targeting of specific neuronal subtypes. This
selective cell degeneration and death would be expected to initially
favor the appearance of a narrower spectrum of autoantibodies
that are disease-specific. However, as disease pathology advances
in the brain along with widespread inflammation, the declining
local conditions would be expected to negatively affect other
nearby cell types, thus resulting in their loss and the later
appearance of additional autoantibodies reflecting the involvement
of these new cell types. In addition, it is well-known that neuronal
degeneration in one brain region can induce a subsequent
neuronal degeneration in other remote brain regions as a result
of lost connectivity, and that these changes can eventually
compromise the structural and functional integrity of components
of the peripheral nervous system. Thus, the spread of pathology
that is common to many neurodegenerative diseases raises the
possibility that different disease stages may be distinguishable from
one another based on their unique autoantibody profiles that are
dictated by their current pathology. Further work will be necessary
to test this possibility.
Benefits of Antigen Identification
One obvious advantage of using protein microarrays to detect
disease-associated autoantibodies in sera is that the identities of
both the autoantibodies and their antigen targets become known.
This knowledge may prove to be beneficial to drug discovery and
other therapeutic efforts, especially if these identities shed new
light on key components of disease-relevant pathways that can be
specifically targeted. Currently, little is known about many of the
antigens identified here as targets of PD-specific autoantibody
biomarkers. However, some common patterns are beginning to
emerge. For example, the biomarker antigen discussed above,
FRMD8, has also been shown to be an effective diagnostic
indicator for Alzheimer’s disease [18]. Overlap of useful diagnostic
indicators is not surprising, since both diseases involve the
degeneration and death of closely similar cell type (both are brain
neurons). As more is learned about the functions of serum
Table 3. Diagnostic Accuracies of Selected Biomarkers.
PD (n=29) vs.
All Controls Older Control Younger Control AD* Breast Cancer MS
n=40 n=20 n=20 n=50 n=30 n=10
Sensitivity % 93.1 96.6 96.6 79.3 100.0 100.0
Specificity % 100.0 100.0 100.0 90.0 93.3 100.0
PPV% 100.0 100.0 100.0 82.1 93.5 100.0
NPV % 95.2 95.2 95.2 88.2 100.0 100.0
*The biomarkers used for this classification are those of Table 5 in our previous work [18]; all others are the biomarkers identified in Table 2.
doi:10.1371/journal.pone.0032383.t003
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understanding of autoantibody profiles will eventually yield
significant research and therapeutic benefits.
Other PD Diagnostics
Many potential protein biomarkers in the blood and cerebro-
spinal fluid have been pursued for the diagnosis and staging of PD.
DJ-1 and a-synuclein, two proteins critically involved in PD
pathogenesis, have been tested as potential disease biomarkers, but
results have been inconsistent [23,24]. CSF levels of a-synuclein
show a decrease or no change between patients with PD and
controls [25–27]. Even a -synuclein-reactive antibodies have been
pursued as diagnostic biomarkers of PD. Studies have shown
significantly higher antibody levels towards monomeric a-
synuclein in the sera of PD patients when compared to controls,
but these responses decreased with PD progression [28]. Several
other potential protein biomarkers for PD are currently being
investigated but the results have been highly variable and
somewhat non-specific. The detection of disease-specific serum
autoantibodies with the potential to accurately and specifically
diagnose PD presents a hitherto unexplored new avenue for
continued research into PD etiology, diagnosis, and treatment.
Conclusion
There is a profound need for accurate and specific biomarkers
to aid in the primary diagnosis of PD. The 10 autoantibody
biomarkers identified here have demonstrated a diagnostic
sensitivity of 93.1% and specificity of 100% in differentiating PD
sera from healthy controls. Similar accuracies were obtained when
differentiating PD sera from other diseases. A reliable blood test
for PD will have a tremendous clinical impact, not only to patients
and their physicians, but also to pharmaceutical companies trying
to gauge the effectiveness of disease-modifying drugs in clinical-
trials. The relative non-invasiveness, broad availability, low cost,
and versatility of protein microarrays make a technology of this
kind well-suited for incorporation into routine health care. We
hope that early, perhaps even pre-symptomatic, screening
methods can be established for the betterment of patients. More
than that, we view serum autoantibodies as an exciting new class of
pathologically-relevant molecules that can be explored for better
comprehension of disease mechanisms and potential therapies.
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